A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma
Abstract Background Lung cancer is one of the most lethal and most prevalent malignant tumors worldwide, and lung squamous cell carcinoma (LUSC) is one of the major histological subtypes. Although numerous biomarkers have been found to be associated with prognosis in LUSC, the prediction effect of a...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08360-z |
id |
doaj-fecb9d182c8b49e7a9921ed120cbef70 |
---|---|
record_format |
Article |
spelling |
doaj-fecb9d182c8b49e7a9921ed120cbef702021-05-30T11:49:28ZengBMCBMC Cancer1471-24072021-05-0121111110.1186/s12885-021-08360-zA glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinomaGuichuan Huang0Jing Zhang1Ling Gong2Yi Huang3Daishun Liu4Department of Pulmonary and Critical Care Medicine, The First People’s Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University)Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Zunyi Medical UniversityDepartment of Pulmonary and Critical Care Medicine, The First People’s Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University)Department of Pulmonary and Critical Care Medicine, The First People’s Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University)Department of Pulmonary and Critical Care Medicine, The First People’s Hospital of Zunyi (The Third Affiliated Hospital of Zunyi Medical University)Abstract Background Lung cancer is one of the most lethal and most prevalent malignant tumors worldwide, and lung squamous cell carcinoma (LUSC) is one of the major histological subtypes. Although numerous biomarkers have been found to be associated with prognosis in LUSC, the prediction effect of a single gene biomarker is insufficient, especially for glycolysis-related genes. Therefore, we aimed to develop a novel glycolysis-related gene signature to predict survival in patients with LUSC. Methods The mRNA expression files and LUSC clinical information were obtained from The Cancer Genome Atlas (TCGA) dataset. Results Based on Gene Set Enrichment Analysis (GSEA), we found 5 glycolysis-related gene sets that were significantly enriched in LUSC tissues. Univariate and multivariate Cox proportional regression models were performed to choose prognostic-related gene signatures. Based on a Cox proportional regression model, a risk score for a three-gene signature (HKDC1, ALDH7A1, and MDH1) was established to divide patients into high-risk and low-risk subgroups. Multivariate Cox regression analysis indicated that the risk score for this three-gene signature can be used as an independent prognostic indicator in LUSC. Additionally, based on the cBioPortal database, the rate of genomic alterations in the HKDC1, ALDH7A1, and MDH1 genes were 1.9, 1.1, and 5% in LUSC patients, respectively. Conclusion A glycolysis-based three-gene signature could serve as a novel biomarker in predicting the prognosis of patients with LUSC and it also provides additional gene targets that can be used to cure LUSC patients.https://doi.org/10.1186/s12885-021-08360-zLung cancerGlycolysisPrognosisGene signature |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Guichuan Huang Jing Zhang Ling Gong Yi Huang Daishun Liu |
spellingShingle |
Guichuan Huang Jing Zhang Ling Gong Yi Huang Daishun Liu A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma BMC Cancer Lung cancer Glycolysis Prognosis Gene signature |
author_facet |
Guichuan Huang Jing Zhang Ling Gong Yi Huang Daishun Liu |
author_sort |
Guichuan Huang |
title |
A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma |
title_short |
A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma |
title_full |
A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma |
title_fullStr |
A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma |
title_full_unstemmed |
A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma |
title_sort |
glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2021-05-01 |
description |
Abstract Background Lung cancer is one of the most lethal and most prevalent malignant tumors worldwide, and lung squamous cell carcinoma (LUSC) is one of the major histological subtypes. Although numerous biomarkers have been found to be associated with prognosis in LUSC, the prediction effect of a single gene biomarker is insufficient, especially for glycolysis-related genes. Therefore, we aimed to develop a novel glycolysis-related gene signature to predict survival in patients with LUSC. Methods The mRNA expression files and LUSC clinical information were obtained from The Cancer Genome Atlas (TCGA) dataset. Results Based on Gene Set Enrichment Analysis (GSEA), we found 5 glycolysis-related gene sets that were significantly enriched in LUSC tissues. Univariate and multivariate Cox proportional regression models were performed to choose prognostic-related gene signatures. Based on a Cox proportional regression model, a risk score for a three-gene signature (HKDC1, ALDH7A1, and MDH1) was established to divide patients into high-risk and low-risk subgroups. Multivariate Cox regression analysis indicated that the risk score for this three-gene signature can be used as an independent prognostic indicator in LUSC. Additionally, based on the cBioPortal database, the rate of genomic alterations in the HKDC1, ALDH7A1, and MDH1 genes were 1.9, 1.1, and 5% in LUSC patients, respectively. Conclusion A glycolysis-based three-gene signature could serve as a novel biomarker in predicting the prognosis of patients with LUSC and it also provides additional gene targets that can be used to cure LUSC patients. |
topic |
Lung cancer Glycolysis Prognosis Gene signature |
url |
https://doi.org/10.1186/s12885-021-08360-z |
work_keys_str_mv |
AT guichuanhuang aglycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT jingzhang aglycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT linggong aglycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT yihuang aglycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT daishunliu aglycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT guichuanhuang glycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT jingzhang glycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT linggong glycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT yihuang glycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma AT daishunliu glycolysisbasedthreegenesignaturepredictssurvivalinpatientswithlungsquamouscellcarcinoma |
_version_ |
1721419994564132864 |